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Methoxy-indolo[2,l-a]isoquinolines 8a-f and their dihydroderivatives 
7a-f were synthesized by Bischler-Napieralski reaction of the (bromo-
methoxyphenyl)-[2-(methoxyphenyl)-ethyl]acetamides 4a-f, reduction, 
subsequent cyclization and dehydrogenation. They were tested for cytosta-
tic activity in vitro using P388 D x leukemia and M D A MB 231 mammary 
tumor cells. The trimethoxy-5,6-dihydroindoloisoquinoline 7d and the te-
tramethoxyindoloisoquinoline 8f showed an inhibition of cellproliferation 
of about 70 % at a concentration of 10"5 molar. 
Synthese und Antitumoraktivität von Methoxy-indolo[2,l-a]isochino-
linen X 
Die Methoxy-indolo[2,l-a]isochinoline 8a-f und deren Dihydroderivate 
7a-f wurden durch Bischler-Napieralski-Ringschluß der (Brom-metho-
xyphenyl)-f2-(methoxyphenyl)-ethyl]acetamide 4a-f, Reduktion, Cycli-
sierung und Dehydrierung gewonnen. Die cytostatische Wirkung wurde 
in vitro an der P388 D r und der MDA-MB 231-Zellinie getestet. Das Tri-
methoxy-5,6-dihydroindoloisochinolin 7d und das Tetramethoxyindolo-
isochinolin 8f zeigten eine Hemmung der Zellproliferation von 70 % bei ei-
ner Konzentration von 10~5 M . 
The aim of our investigations is the synthesis of cytostatic compounds 
with binding affinity for the estrogen receptor, that can be used for the se-
lective treatment of hormone dependent mammary tumors. Suitable struc-
tures for this approach are tetracyclic N-heterocycles, which are known to 
intercalate into the DNA 1 ) and are able to bind to the estrogen receptor2). 
Based on these findings, we synthesized a number of indo-
lo[2,l-a]isoquinolines 8a-f and their dihydro analogues 
7a-f. Cytostatic activity of these compounds was evaluated 
in vitro using M D A - M B 231 mammary tumor cells and 
P388 D1 leukemia cells. 
Chemistry 
The synthesis was performed as outlined in scheme 1. The 
starting methyl bromophenylacetates 2a-c were synthesized 
by bromination of the corresponding phenylacetic acids and 
conversion to the methyl esters. The 2-phenylethylamine 3a 
was obtained directly by L i A l H 4 reduction of the 3-meth-
oxy-ß-nitrostyrene 3 ) or, in better yield, in two steps with 
N a B H 4 followed by L i A l H 4 . The best method was the hy-
drogenation of the 3-methoxy-phenylacetonitrile with Rh /C . 
The reaction of the bromo-phenylacetates 2a-c with the 2-
phenylethylamines 3a and 3b afforded the corresponding 
amides 4a-f. Cyclisation to the 3,4-dihydroisoquinolines was 
accomplished by a modified Bischler-Napieralski method 
using P O C l 3 in C H 3 C N . The crude products were treated 
with N a B H 4 to give the 1,2,3,4-tetrahydro-l-benzylisoqui-
nolines 5a-f. In the case of 4c (2-Bromo-4,5-dimethoxy-
phenyl)-(3,4-dihydro-6-methoxyisoquinolyl-l)-ketone was 
formed as a byproduct, probably by air oxidation4). The cor-
rect substitution pattern in the isoquinoline ring was confir-
med by ^ - N M R spectroscopy. 
The benzylisoquinolines 5a-f were converted into the te-
tracyclic indolo[2,l-a]isoquinolines by treatment with N a H 
in D M S O . This reaction must involve a benzyne interme-
diate5) because both bromo compounds 5a and 5b led to the 
same structure. The reaction mixture contained two products 
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in a ratio of 1:4 which can be separated by column chroma-
tography (CC). The expected tetrahydroindoloisoquinoline 
was only the minor product, whereas the main fraction con-
tained the dihydro derivative. ^ - N M R spectroscopy reveal-
ed, that under the reaction conditions oxidation occures to 
the indoles 7a-f: the double dublett for the hydrogen at 
C-12a had disappeared and two tripletts for the hydrogen 
atoms at C-5 and C-6 appeared instead of the complex multi-
ples in 6b-f. 
This oxidation reaction can also be performed with D D Q 
or with Pd/C at a temp, just above the melting point of the te-
trahydro compound. Heating the dihydro derivative in the 
presence of Pd/C above its melting point, which is considera-
bly higher than that of the tetrahydro compound, afforded 
the aromatic indoloisoquinolines 8a-f. 
to the aromatic indoloisoquinolines 8a-f, no significant in-
crease of cytostatic activity was observed. The tetramethoxy 
derivative 8f was the most active compound in this series 
(Table 2). 
These results showed, that cytostatic activity is not gene-
rally associated with a planar structure of the tetracyclic he-
terocycles. Compounds with a significant inhibition of cell 
growth possess a dimethoxyisoquinoline fragment (8d, 8f, 
7d). This effect was not very marked, since a concentration 
of 10"5 M was required for it. The rather low activity of this 
type of tetracycles may be due to the lack of a positive charge 
on the nitrogen. 
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Cytostatic Activity 
Two different cell lines were used for the determination 
of cytostatic activity. The P388 D j cell line derives from a 
mouse leukemia, the M D A - M B 231 cells are hormone-inde-
pendent mammary tumor cells of human origin. A l l of the 
new indoloisoquinolines were tested for cytostatic effects at a 
concentration of 10"5 molar. The inhibition of cell growth was 
measured by cell counting and 3H-thymidine labeling. The 
tetrahydro derivatives 6b-f were devoid of activity, probably 
due to their nonplanar structure. The dihydro compounds 7 
showed a weak inhibitory effect except compound 7d that 
proved to be active against M D A - M B 231 (Table 1). Going 
Experimental Part 
Melting points: Büchi 510 apparatus, uncorrected. - Elemental analyses: 
Mikroanalytisches Laboratorium, University of Regensburg. - IR-spec-
tra: Beckman Acculab 3; KBr. - 'H-NMR spectra: Varian E M 360 A (60 
MHz); TMS as internal standard. - Temp, in °C. 
General Procedure for the Synthesis of the Bromo-phenylacetic acids 
la-c 
Bromine (17 ml, 0.23 mol) was added slowly to a solution of methoxy-
phenylacetic acid (0.24 mol) (Janssen) and 10.7 g (0.27 mol) of NaOH in 
400 ml water at 50°. After stirring for 30 min and cooling to room temp., 
the precipitate was filtered off and washed with water. Recrystallization 
from aqueous MeOH yielded colorless crystals. 
Tab. 1: Effect of 7a-f on the growth of MDA-MB 231 and P388 Dx cells 
P388 Di MDA-MB 231 
Compound3) cell no.b) 3H-thymidine cell no. b> 3H-thymidine 
incorp.c) incorp.c) 
%T/Cd> %T/Cd> %T/Cd> %T/C d) 
7a 95 98 90 90 
7b 100 97 100 98 
7c 93 93 87 90 
Id 96 92 32 16 
7de> 90 90 
7e 96 93 87 62 
7f 93 93 93 92 
a) Concentration 10~5 M. 
b) Mean of three tests with six dishes/test tubes. 
c) cpm/106 cells. 
d) % T/C = test compound/control X 100. 
e) Concentration 10 " 6 M. 
Tab. 2: Effect of Sa--f on the growth of MDA-MB 231 and P388 D x cells 
P388 Di MDA--MB 231 
Compound3) cell no.b> 3H-thymidine cell no.b> 3H-thymidine 
% T/Cd> 
incorp.c) 
% T/Cd> % T/Cd> 
incorp.c) 
% T/Cd> 
8a 89 92 82 85 
8b 78 84 80 85 
8c 88 95 84 90 
8d 71 73 48 45 
8e 73 78 97 100 
8f 30 15 48 21 
a, b, c, d) see Tab. 1. 
2-Bromo-5-methoxy-phenylacetic acid (la) 
Yield 90 %; m.p. 115° (lit. 114-115° 6)). - ^ - N M R (CDC13): 5 (ppm) = 
3.8 (s; 5H, -OCH 3 , -CH 2-), 6.67-6.9 (m; 2H, ArH), 7.47 (d; J = 9 Hz, 1H, 
ArH), 7.96 (s broad; 1H, OH). 
2- Bromo-4,5-dimethoxy-phenylacetic acid (lb) 
Yield 90 %; m.p. 115° (lit. 115-116° 6>). - 'H-NMR (CDC13): 8 (ppm) = 
3.77 (s; 2H, -CH 2-), 3.88 (s; 6H, -OCH 3), 6.76 (s; 1H, ArH), 7.02 (s; 1H, 
ArH), 8.16 (s broad; 1H, OH). 
3- Bromo-4-methoxy-phenylacetic acid (lc) 
Yield 80 %; m.p. 115° (lit. 115° % - 'H-NMR (CDC13): 5 (ppm) = 3.8 
(s; 5H, -OCH 3 , - C H 2 ) , 6.67-6.9 (m; 2H, ArH), 7.47 (d; J = 9 Hz, 1H, 
ArH), 7.96 (s broad; 1H, OH). 
General Procedure for the Synthesis of the Methyl Bromo-methoxyphe-
nylacetates 2a-c 
Bromo-methoxyphenylacetic acid (0.23 mol) in 180 ml absol. MeOH and 
6 ml cone. H 2 S 0 4 was boiled for 17 h. The volume of the solution was re-
duced to 50 ml. After addition of 100 ml of water, the mixture was extract-
ed with CH 2 C1 2 . The org. layer was dried (Na 2S0 4) and the solution was 
evaporated. 
Methyl 2-bromo-5-methoxyphenylacetate (2a) 
The product was purified by Kugelrohr-distillation: colorless oil. - Yield 
90 %; b.p. 77-80°, 0.2 mm. - C 1 0 H n B r O 3 (259.0) Calc. C 46.4 H 4.25 
Found C 47.0 H 4.61. - IR (film): 1740 (CO) cm-1. - ^ - N M R (CDC13): 
8 (ppm) = 3.70 (s; 2H, -CH 2-), 3.76 (s; 3H, COOCH 3 ) , 3.80 (s; 3H, 
-OCH 3), 6.6-6.9 (m; 2H, ArH), 7.43 (d; J = 9 Hz, 1H, ArH). 
Methyl 2-bromo-4,5-dimethoxyphenylacetate (2b) 
The product was recrystallized from aqueous MeOH: colorless crystals. 
Yield 80 %; m.p. 48°. - C n H 1 3 B r 0 4 (289.1) Calc. C 45.7 H 4.53 Found 
C45.4 H4.68. - IR (KBr): 1740 (CO) cm - 1 . - J H-NMR (CDC13): 
5 (ppm) = 3.77 (s; 5H, C O O C H 3 , -CH 2-), 3.91 (s; 6H, -OCH 3), 6.87 (s; 
1H, ArH), 7.13 (s; 1H, ArH). 
Methyl 3-bromo-4-methoxyphenylacetate (2c) 
Recrystallization from aqueous MeOH yielded colorless crystals. Yield 
90 %; m.p. 31° (lit. 48° 8>). - C 1 0 H n B r O 3 (259.0) Calc. C 46.4 H 4.25 
Found C 46.2 H 4.35. - IR(KBr): 1740 (CO) cm-1. - J H-NMR (CDC13): 
6 (ppm) = 3.6 (s; 2H, -CH 2-), 3.73 (s; 3H, -COOCH 3 ) , 3.9 (s; 3H, 
-OCH 3), 6.86 (d; J = 9 Hz, 1H, ArH), 7.23 (dd; J 1 ? 2 = 9/2 Hz, 1H, 
ArH), 7.5 (d; J = 2 Hz, 1H, ArH). 
l-Amino-2-(3-methoxyphenyl)-ethane (3a) 
1 g Rh/C 10 % was added to a solution of 50 g (0.34 mol) 3-methoxy-phe-
nylacetonitrile (Janssen) dissolved in 110 ml EtOH saturated with N H 3 . 
The mixture was hydrogenated at 30 bar for 7 d. The catalyst was filtered 
off, washed with EtOH, and the solvent was evaporated. Pure 3a was ob-
tained as colorless oil. Yield 98 %; b.p. 122-123°, 7 mm (lit. 122-123°, 
7 mm*)). - 'H-NMR (CDC13): 6 (ppm) = 1.48 (s; 2H, -NH 2), 2.82 (mc; 
4H, - C H 2 ) , 3.79 (s; 3H, -OCH 3), 6.59-7.3 (m; 4H, ArH). 
General Procedure for the Synthesis of the Acetamides 4a-f 
A flask containing 0.75 mol methoxy-phenylethylamine and 0.75 mol me-
thyl bromo-phenylacetate was placed into a hot oil bath. The temp, was 
kept at 150-155° for 10h. After cooling to 35° 10 ml EtOAc were added 
with stirring. The product crystallizing at 4° was filtered off and washed 
with ether. Acetamides, which did not crystallize spontaneously, were pu-
rified by CC (Si0 2; ether/CHCl3 1:1) and crystallized from EtOAc/ether. 
The crystals of 4a-f are colorless. 
2-(2-Bromo-5-methoxyphenyl)-N-f2-(3-methoxyphenyl-ethyl1-acetamide 
(4a) 
4a was synthesized from 2a and 3a and recrystallized from EtOH. Yield 
50%; m.p. 91°. - C 1 8 H 2 0 B r N O 3 (378.3) Calc. C 57.2 H 5.35 Found 
C 57.2 H 5.28. - IR(KBr): 3300 (NH), 1650, 1555 (CO) cm-1. - lH-
N M R (CDC13): 8 (ppm) = 2.80 (t; J = 7 Hz, 2H, -CH 2-), 3.53 (t; J = 7 Hz, 
2H, -CH 2-), 3.67 (s; 2H, - C O C H 2 ) , 3.83 (s; 3H, -OCH 3), 3.93 (s; 3H, 
-OCH 3), 5.53 (s broad; 1H, -NH), 6.67-7.43 (m; 6H, ArH), 7.77 (s; 1H, 
ArH). 
2-(3-Bromo-4-methoxyphenyl)-N-f2-(3-methoxyphenyl)-ethyl/-acetamide 
(4b) 
4b was synthesized from 2c and 3a and recrystallized from EtOAc/ether 
(7+3). Yield 55 %; m.p. 63-64°. - C 1 8 H 2 0 B r N O 3 (378.3) Calc. C 57.2 
H 5.35 Found C .56.8 H 5.43. - *H-NMR (CDC13): 8 (ppm) = 2.73 (t; J = 
7 Hz, 2H, - C H 2 ) , 3.3-3.53 (m; 4H, -COCH 2 - , -CH 2-), 3.77 (s; 3H, 
-OCH 3), 3.87 (s; 3H, -OCH 3), 5.49 (s broad; 1H, -NH), 6.56-6.79 (m; 
3H, ArH), 6.86 (s; 1H, ArH), 7.0-7.17 (m; 2H, ArH), 7.34 (d; J = 2 Hz, 
1H, ArH). 
2-(2-Bromo-4,5-dimethoxyphenyl)-N-[2-(3-methoxyphenyl)-ethyll-acet-
amide (4c) 
4c was synthesized from 2b and 3a and recrystallized from EtOH. Yield 
60 %; m.p. 145-146.5°. - C 1 9 H 2 2 B r N 0 4 (408.3) Calc. C 55.9 H 5.39 
Found C 55.8 H 5.40. - 'H-NMR (CDC13): 8 (ppm) = 2.77 (t; J = 7 Hz, 
2H, - C H 2 ) , 3.47 (t; J = 7 Hz, 2H, -CH 2-), 3.63 (s; 2H, - C O C H 2 ) , 3.82 (s; 
3H, -OCH 3), 3.85 (s; 3H, -OCH 3), 3.90 (s; 3H, -OCH 3), 5.50 (s broad; 
1H, -NH), 6.65-7.33 (m; 6H, ArH). 
2-(2-Bromo-5-methoxyphenyl)-N-[2-(3,4-dimethoxyphenyl)-ethyl/-acet-
amide (4d) 
4d was synthesized from 2a and l-amino-2-(3,4-dimethoxyphenyl)-ethane 
(3b) (Janssen) and recrystallized from EtOH. Yield 55 %; m.p. 128-129°. 
- C 1 9 H 2 2 B r N 0 4 (408.3) Calc. C 55.9 H 5.39 Found C 55.4 H 5.70. - 1 H -
N M R (CDC13): 8 (ppm) = 2.70 (t; J = 7 Hz, 2H, -CH 2-) 3.42 (t; J = 7 Hz, 
2 H , -CH 2-), 3.60 (s; 2H, -COCH 2-), 3.73 (s; 3H, -OCH 3), 3.80 (s; 3H, 
-OCH 3), 3.82 (s; 3H, -OCH 3), 5.53 (s broad; 1H, -NH), 6.63-6.85 (m; 
5H, ArH), 7.43 (d; J = 9 Hz, 1H, ArH). 
2-(3-Bromo-4-methoxyphenyl)-N-f2,-(3,4-dimethoxyphenyl)-ethyll-acet-
amide (4e) 
4e was synthesized from 2c and 3b and recrystallized from EtOH. Yield 
50%; m.p. 123-124° - C 1 9 H 2 2 B r N 0 4 (408.3) Calc. C 55.9 H 5.39 
Found C 55.9 H 5.44. - *H-NMR (CDC13): 8 (ppm) = 2.73 (t; J = 7 Hz, 
2H, -CH 2-), 3.42 (t; J = 7 Hz, 2H, -CH 2-), 3.47 (s; 2H, -COCH 2-), 3.88 (s; 
3H, -OCH 3), 3.93 (s; 3H, -OCH 3), 3.95 (s; 3H, -OCH 3), 5.55 (s broad; 
1H, -NH), 6.67-7.0 (m; 4H, ArH), 7.18 (dd; J 1 / 2 = 9/2 Hz, 1H, ArH), 
7.45 (d; J = 2 Hz, 1H, ArH). 
2-(2-Bromo-4,5-dimethoxyphenyl)-N-[2-(3,4-dimethoxyphenyl)-ethyl/-
acetamide (4f) 
4f was synthesized from 2b and 3b and recrystallized from EtOH. Yield 
60%; m.p. 158.5-159°. - C 2 0 H 2 4 B r N O 5 (438.3) Calc. C 54.8 H 5.52 
Found C 54.9 H 5.53. - ] H - N M R (CDC13): 8 (ppm) = 2.73 (t; J = 7 Hz, 
2H, -CH 2-), 3.47 (t; J = 7 Hz, 2H, -CH 2-), 3.63 (s; 2H, - C O C H 2 ) , 3.87 (s; 
12H, -OCH 3), 5.57 (s broad; 1H, -NH), 6.67-7.07 (m; 5H, ArH). 
General Procedure for the Synthesis of the 1-Benzyl-1,2,3,4-tetrahydro-
isoquinolines 5a-f 
A mixture of 55 mmol of acetamide, 20 ml of POCl 3 and 75 ml of absol. 
C H 3 C N was refluxed for 4 h. With cooling, 150 ml of 20 % NaOH solu-
tion were added, the mixture was poured onto ice water and extracted with 
CHC1 3 . The CHCI3 solution was extracted with 150 ml 2N HCl . The free 
base was liberated with 20 % NaOH and extracted with CHC1 3 . The org. 
layer was washed with water and saline, and dried (Na 2S0 4). The 3,4-di-
hydroisoquinolines obtained after evaporation of the solvent were used 
without further purification. The yields were between 55 and 70 %. Air 
must be excluded as far as possible during workup. 
NaBH 4 (0.11 mol) was added slowly to a solution of 13.4 mmol of 3,4-di-
hydroisoquinoline in 100 ml MeOH and 15 ml water at 0°. The mixture 
was stirred for 2 h at room temp. After the solvent had been removed, the 
residue was treated with 100 ml water and extracted with CHC1 3 . The org. 
layer was washed with water, and dried (Na 2S0 4). After evaporation of 
the solvent the residue crystallized with aqueous EtOH or was purified by 
CC (Si0 2; CHCl3/ether 1:1). Recrystallization from aqueous EtOH af-
forded colorless crystals. The yields were 58-80 %. 
1 -(2-Bromo-5-methoxybenzyl)-l ,2,3,4-tetrahydro-6-methoxyisoquinoline 
(5a) 
Yield 50 %; m.p. 72-74°. - C 1 8 H 2 0 B r N O 2 (362.3) Calc. C 59.7 H 5.56 
Found C 59.3 H 5.54. - IR (KBr): 3350 (NH) cm-1. - *H-NMR (CDC13): 
8(ppm) = 1.79 (s broad; 1H, -NH), 2.67-3.53 (m; 6H, -CH 2-), 3.80 (s; 
6H, -OCH 3), 4.31 (dd; J 1 / 2 = 10/4 Hz, 1H, -CH-N), 6.58-6.87 (m; 4H, 
ArH), 7.26 (d; J = 9 Hz, 1H, ArH), 7.48 (d; J = 9 Hz, 1H, ArH). 
l-(3-Bromo-4-methoxybenzyl)-l ,2,3,4-tetrahydro-6-methoxyisoquinoline 
(5b) 
Yield 70 %; m.p. 97-98°. - C 1 8 H 2 0 B r N O 2 (362.3) Calc. C 59.7 H 5.56 
Found C 59.0 H 5.68. - *H-NMR (CDC13): 8 (ppm) = 2.57 (s, broad; 1H, 
-NH), 2.73-3.30 (m; 6H, -CH 2-), 3.77 (s; 3H, -OCH 3), 3.87 (s; 3H, 
-OCH 3), 4.15(dd;J 1 / 2= 10/4 Hz, 1H, -CH-N), 6.59-6.82 (m; 3H, ArH), 
6.88 (s; 1H, ArH), 7.1-7.28 (m; 2H, ArH), 7.47 (d; J = 2 Hz, 1H, ArH). 
1 -(2-Bromo-4,5-dimethoxybenzyl)-l ,2,3,4-tetrahydro-6-methoxyisoqui-
noline (5c) 
Yield 60%; m.p. 114°. - C 1 9 H 2 2 B r N 0 3 (392.3) Calc. C 58.2 H 5.65 
Found C 57.7 H 5.51. - ^ - N M R (CDC13): 8 (ppm) = 2.0 (s broad; 1H, 
-NH), 2.70-3.40 (m; 6H, -CH 2-), 3.83 (s; 3H,- OCH 3 ) , 3.87 (s; 3H, 
-OCH 3), 3.92 (s; 3H, -OCH 3), 4.33 (dd; J 1 / 2 = 10/4 Hz, 1H, -CH-N), 
6.70-6.90 (m; 3H, ArH), 7.15 (s; 1H, ArH), 7.30 (d; J = 9 Hz, 1H, ArH). 
(2-Bromo-4,5-dimethoxyphenyl)-(3,4-dihydro-6-methoxyisoquinolyl-l-)-
ketone 
This compound was formed as a byproduct of the cyclization of 4c. It was 
purified by CC (Si0 2; CH 2C1 2) to afford colorless crystals. Yield 20 %; 
m.p. 180-181°. - C 1 9 H 1 8 B r N 0 4 (404.3) Calc. C 56.4 H 4.46 Found 
C 56.0 H 4.62.-IR(KBr): 1670 (CO) cnr 1. - *H-NMR (CDC13): 8 (ppm) 
= 2.80 (t: J = 7 Hz, 2H, - C H 2 ) , 3.80 (t; J = 7 Hz, 2H, -CH 2-), 3.90 (s; 3H, 
-OCH 3), 3.95 (s; 6H, -OCH 3), 6.80-6.97 (m; 2H, ArH), 7.27 (s; 1H, 
ArH), 7.63 (d; J = 9 Hz, 1H, ArH). 
1 -(2-Bromo-5-methoxy benzyl)-! ,2,3,4-tetrahydro-6,7-dimethoxyisoqui-
noline (5d) 
Yiey 65%; m.p. 117°. - C 1 9 H 2 2 B r N 0 3 (392.3) Calc. C 58.2 H 5.65 
Found C 58.0 H 5.55. - ! H - N M R (CDC13): 8 (ppm) = 1.90 (s broad; 1H, 
-NH), 2.67-3.50 (m; 6H, - C H 2 ) , 3.73 (s; 3H, -OCH 3), 3.77 (s; 3H, 
-OCH 3), 3.82 (s; 3H, -OCH 3), 4.33 (dd; J 1 / 2 = 10/4 Hz, 1H, -CH-N), 6.57 
(s; 1H, ArH), 6.58-6.83 (m; 2H, ArH), 6.72 (s; 1H, ArH), 7.47 (d; J = 
9 Hz, 1H, ArH). 
l-(3-Bromo-4-methoxybenzyl)-l,2,3,4-tetrahydro-6J-dimethoxyisoqui-
noline (5e) 
Yield 55 %; m.p. 107-109°. - C 1 9 H 2 2 B r N 0 3 (392.3) Calc. C 58.2 H 5.65 
Found C 57.8 H 5.62. - *H-NMR (CDC13): 8 (ppm) = 1.80 (s broad; 1H, 
-NH), 2.67-3.50 (m; 6H, - C H 2 ) , 3.88 (s; 3H, -OCH 3), 3.92 (s; 3H, 
-OCH 3), 3.95 (s; 3H, -OCH 3), 4.17 (dd; J 1 / 2 = 10/4 Hz, 1H, -CH-N), 6.70 
(s; 2H, ArH), 6.90 (d; J = 9 Hz, 1H, ArH), 7.27 (dd; J 1 / 2 = 9/2 Hz, 1H, 
ArH), 7.57 (d; J = 2 Hz, 1H, ArH). 
1 -(2-Bromo-4,5-dimethoxybenzyl)-l,2,3,4-tetrahydro-6,7-dimethoxyiso-
quinoline (5f) 
Yield 80 %; m.p. 107-109° (lit. 111° 10>). 
General Procedure for the Ring Closure of the Bromo-tetrahydrobenzyl-
isoquinolines to the Tetrahydro- and Dihydro-indolol 2,1-ajisoquinolines 
6b-f and 7a-f 
A solution of bromo-tetrahydro-benzylisoquinoline (10 mmol) in 40 ml 
DMSO was added to a solution of sodium methylsulfinylmethanide (pre-
pared from 2.1 g (70 mmol) NaH (80 % in oil dispersion) and 40 ml 
DMSO). After stirring had been continued for 15 h, the mixture was pour-
ed into 400 ml water containing excess NH 4C1 and extracted with CHC1 3. 
The org. layer was washed with water and saline. After drying (Na 2S0 4), 
evaporation of the solvent afforded a brownish oil, which was chromato-
graphed (Si0 2; CH 2C1 2). The first fraction (Rf 0.7) contained the dihydro-
indoloisoquinolines as main product. The tetrahydro-indoloisoquinolines 
were isolated as second fraction (Rf 0.3). Both products were recrystalli-
zed from EtOH to afford colorless crystals. Their yields ranged from 40 to 
70 %. - In the case of 5a no tetrahydro product was isolated. 
5,6,12,12a-Tetrahydro-3,9-dimethoxy-indolo[2,l-a]isoquinoline (6b) 
M.p. 53-54°. - C 1 8 H 1 9 N 0 2 (281.3) Calc. C 76.8 H 6.81 Found C 76.6 
H 6.77. - 'H-NMR (CDC13): 8 (ppm) = 2.53-3.66 (m; 6H, -CH 2-), 3.76 
(s; 3H, -OCH 3), 3.79 (s; 3H, -OCH 3), 4.69 (dd; J 1 / 2 = 8/3 Hz, 1H, 
-CH-N), 6.1-7.2 (m; 6H, ArH). 
5,6,12,12a-Tetrahydro-3,9,10-trimethoxy-indolo[2,l-a1isoquinoline (6c) 
M.p. 101°. - C 1 9 H 2 1 N 0 3 (311.4) Calc. C 73.3 H 6.80 Found C 73.0 
H 6.89. - *H-NMR (CDC13): 8 (ppm) = 2.43-3.67 (m; 6H, -CH 2-), 3.82 
(s; 6H, -OCH 3), 3.93 (s; 3H, -OCH 3), 4.92 (dd; J 1 / 2 = 8/3 Hz, 1H, 
-CH-N), 6.40 (s; 1H, ArH), 6.65-7.0 (m; 3H, ArH), 7.27 (d; J = 9 Hz, 
1H, ArH). 
5,6,12,12a-Tetrahydro-2,3,10-trimethoxy-indolo[2,l-a/isoquinoline (6d) 
M.p. 128-129°. - C 1 9 H 2 1 N 0 3 (311.4) Calc. C 73.3 H 6.80 Found C 73.2 
H 6.80. - *H-NMR (CDC13): 8 (ppm) = 2.33-3.80 (m; 6H, -CH 2-), 3.67 
(s; 3H, -OCH 3), 3.77 (s; 3H, -OCH 3), 3.83 (s; 3H, -OCH 3), 4.82 (dd; 
J 1 / 2 = 8/3 Hz, 1H, -CH-N), 6.45 (s; 1H, ArH), 6.55-6.70 (m; 4H, ArH). 
5,6,12,12a-Tetrahydro-2,3,9-trimethoxy-indolo[2,1a lisoquinoline (6e) 
M.p. 120-121°. - C 1 9 H 2 1 N 0 3 (311.4). - Calc. C 73.3 H 6.80 Found 
C73.2 H6.79. - 'H-NMR (CDC13): 8 (ppm) = 2.50-3.77 (m; 6H, 
- C H 2 ) , 3.77 (s; 3H, -OCH 3), 3.83 (s; 3H, -OCH 3), 3.90 (s; 3H, -OCH 3), 
4.87 (dd; J 1 / 2 = 8/3 Hz, 1H, -CH-N), 6.10-6.27 (m; 2H, ArH), 6.50 (s; 
1H, ArH), 6.67 (s; 1H, ArH), 6.95 (d; J = 9 Hz, 1H, ArH). 
5,6,12,12a-Tetrahydro-2,3,9,10-tetramethoxy-indolo[2,lalisoquinoline 
(60 
M.p. 105-107° (lit. 105-107° ">). 
5,6-Dihydro-3,10-dimethoxy-indolo[2,l-a]isoquinoline (7a) 
M.p. 208°. - C 1 8 H 1 7 N 0 2 (279.3) Calc. C 77.4 H6.13 Found C 76.9 
H 6.05. - *H-NMR (CDC13): 8 (ppm) = 3.16 (t; J = 7 Hz, 2H, - C H 2 ) , 
3.83 (s; 6H, -OCH 3), 4.19 (t; J = 7 Hz, 2H, - C H 2 ) , 6.65-7.10 (m; 6H, 
ArH, vinyl-H), 7.61 (d; J = 9 Hz, 1H, ArH). 
5,6-Dihydro-3,9-dimethoxy-indolo[2,l-aJisoquinoline (7b) 
M.p. 176°. - C 1 8 H 1 7 N 0 2 (279.3) Calc. C 77.4 H6.13 Found C 77.6 
H 6.30. - *H-NMR (CDC13): 8 (ppm) = 3.1 (t; J = 7 Hz, 2H, - C H 2 ) , 3.77 
(s; 3H, -OCH 3), 3,85 (s; 3H, -OCH 3), 4.13 (t; J = 7 Hz, 2H, - C H 2 ) , 
6.48-6.86 (m; 5H, ArH, vinyl-H), 7.48 (d; J = 9 Hz, 1H, ArH), 7.66 (d; 
J = 9 Hz, 1H, ArH). 
5,6-Dihydro-3,9,10-trimethoxy-indolol'2,1-a/isoquinoline (7c) 
M.p. 212°. - C 1 9 H 1 9 N 0 3 (309.4) Calc. C 73.8 H6.19 Found C 73.9 
H 6.15. - *H-NMR (CDC13): 5 (ppm) = 3.18 (t; J = 7 Hz, 2H, - C H 2 ) , 
3.87 (s; 3H, -OCH 3), 3.90 (s; 3H, -OCH 3), 3.97 (s; 3H, -OCH 3), 4.20 (t; 
J = 7 Hz, 2H, -CH 2-), 6.70 (s; 1H, vinyl-H), 6.83-7.02 (m; 3H, ArH), 
7.12 (s; 1H, ArH), 7.70 (d; J = 9 Hz, 1H, ArH). 
5,6-Dihydro-2,3,l 0-trimethoxy-indolol 2,1 -a Hsoquinoline (7d) 
M.p. 217°. - C 1 9 H 1 9 N 0 3 (309.4) Calc. C 73.8 H6.19 Found C 73.6 
H 6.09. - *H-NMR (CDC13): 6 (ppm) = 3.15 (t; J = 7 Hz, 2H, - C H 2 ) , 
3.90 (s; 3H, -OCH 3), 3.95 (s; 3H, -OCH 3), 4.00 (s; 3H, -OCH 3), 4.23 (t; 
J - 7 Hz, 2H, -CH 2-), 6.73 (s; 1H, vinyl-H), 6.83 (s; 1H, ArH), 6.93-7.37 
(m; 4H, ArH). 
5,6-Dihydro-2,3,9-trimethoxy-indolo[2,1-aJisoquinoline (7e) 
M.p. 198°. - C 1 9 H 1 9 N 0 3 (309.4) Calc. C 73.8 H6.19 Found C 73.5 
H 6.15. - *H-NMR (CDC13): 8 (ppm) = 3.10 (t; J = 7 Hz, 2H, - C H 2 ) , 
3.88 (s; 3H, -OCH 3), 3.90 (s; 3H, -OCH 3), 3.95 (s; 3H, -OCH 3), 4.17 (t; 
J = 7 Hz, 2H, - C H 2 ) , 6.73-6.83 (m; 4H, ArH, vinyl-H), 7.20 (s; 1H, 
ArH), 7.52 (d; J = 9 Hz, 1H, ArH). 
5,6-Dihydro-2,3,9,10-tetramethoxy-indolo[2,l-a]isoquinoline (7f) 
M.p. 209-210° (lit. 209-210° »>). 
General Procedure for the Dehydrogenation of the Dihydroindoloisoqui-
nolines to the Indolo[2,l-a]isoquinolines 8a-f with Pd/C 
Dihydro-indolo[2,l-a]isoquinoline (1.3 mmol) and Pd/C 10 % (150 mg) 
were mixed thoroughly in an agate mortar. This and all of the following 
operations were carried out under N 2 . A flask containing the mixture was 
placed in an oil bath of a temp, which was kept 10-15° above the melting 
point of the dihydro-indoloisoquinoline. After 30 min, the mixture was 
stirred with a spatula. Heating was continued for 30 min. After cooling, 
the mixture was dissolved in CH 2 C1 2 and filtrated. The solvent was evapo-
rated and the residue was chromatographed (Si0 2; CH 2C1 2). Recrystalli-
zation from EtOH afforded colorless crystals. The yields were 80-90 %. 
3,10-Dimethoxy-indolol2,1 -aHsoquinoline (8a) 
Yield 80%; m.p. 255-256°. - C 1 8 H 1 5 N 0 2 x 1/4 H 2 0 (281.4) Calc. 
C 76.8 H 5.55 Found C 76.8 H 5.53. - IR (KBr): 3420 (H zO) cm-1. - ' H -
N M R (CDC13): 8 (ppm) = 3.93 (s; 6H, -OCH 3), 6.62, 7.67 (AB; J = 9 Hz, 
2H, ArH), 6.87-7.24 (m; 5H, ArH), 7.93-8.13 (m; 2H, ArH). 
3,9-Dimethoxy-indolo[2,l-a]isoquinoline (8b) 
Yield 85 %; m.p. 217°. - C 1 8 H 1 5 N 0 2 x 1/4 H 2 0 (281.4) Calc. C 76.8 
H 5.55 Found 76.7 H 5.69. - *H-NMR (CDC13): 8 (ppm) = 3.90 (s; 3H, 
-OCH 3), 3.93 (s; 3H, -OCH 3), 6.5-7.23 (m; 6H, ArH), 7.58-8.07 (m; 3H, 
ArH). 
3,9,10-Trimethoxy-indolo[2,l-aIisoquinoline (8c) 
Yield 80%; m.p. 230°. - C 1 9 H 1 7 N 0 3 x 1/4 H 2 0 (3U.4) Calc. C 73.2 
H 5.66 Found C 73.2 H 5.85. - *H-NMR (CDC13): 8 (ppm) = 3.92 (s; 
3H, -OCH 3), 3.97 (s; 3H, OCH 3 ) , 4.01 (s; 3H, -OCH 3), 6.58, 7.93 (AB; 
J = 9 Hz, 2H, ArH), 6.93 (s; 1H, ArH), 6.98 (s; 1H, ArH), 7.15-7.26 (m; 
3H, ArH), 7.98 (d; J = 9 Hz, 1H, ArH). 
2,3,10-Trimethoxy-indolo[2,l-a]isoquinoline (8d) 
Yield 55%; m.p. 217-218°. - C 1 9 H 1 7 N 0 3 x 1/4 H 2 0 (311.4) Calc. 
C 73.2 H 5.66 Found C 73.3 H 5.75. - 'H-NMR (CDC13): 8 (ppm) = 
3.97 (s; 3H, -OCH 3), 4.05 (s; 3H, -OCH 3), 4.12 (s; 3H, -OCH 3), 6.72 (d; J 
= 9 Hz, 1H, ArH), 6.97-7.37 (m; 4H, ArH), 7.60 (s; 1H, ArH), 7.80 (d; J 
= 9 Hz, 1H, ArH), 8.10 (d; J = 9 Hz, 1H, ArH). 
2,3,9- Trimethoxy-indolof2,1-aHsoquinoline (8e) 
Yield 60 %; m.p. 217°. - C 1 9 H 1 7 N 0 3 x 1/4 H 2 0 (311.4) Calc. C 73.2 
H 5.66 Found C 73.0 H 5.66. - *H-NMR (CDC13): 8 (ppm) = 3.98 (s; 
3H, -OCH 3), 4.02 (s; 3H, -OCH 3), 4.08 (s; 3H, -OCH 3), 6.63, 7.93 (AB; J 
= 9 Hz, 2H, ArH), 6.97-7.30 (m; 4H, ArH), 7.53 (s; 1H, ArH), 7.73 (d; J 
= 9 Hz, 1H, ArH). 
2,3,9,10-Tetramethoxy-indolof2,1-aJisoquinoline (8f) 
Yield 75 %; m.p. 210°. - C 2 0 H 1 9 N O 4 x 1/4 H 2 0 (341.4) Calc. C 70.3 
H 5.62 Found C 70.3 H 5.68. - *H-NMR (CDC13): 8 (ppm) = 3.98 (s; 
3H, -OCH 3), 4.02 (s; 6H, -OCH 3), 4.07 (s; 3H, -OCH 3), 6.63, 7.95 (AB; 
J = 9 Hz, 2H, ArH), 6.92 (s; 1H, ArH), 7.0 (s; 1H, ArH), 7.20 (s; 1H, 
ArH), 7.28 (s; 1H, ArH), 7.48 (s; 1H, ArH). 
Biological methods 
P388 Dx Leukemia Cells12) 
Murine P388 Dj leukemia cells were cultured in RMPI 1640 medium 
(Biochrom, Berlin) supplemented with 10 mM HEPES* buffer, 10 % des-
activated horse serum (Biochrom), 2 mM glutamine and 0.085 % 
N a H C 0 3 . Cells were grown in an incubator in 5 % C 0 2 at 37°. Aliquots 
of 2 ml of the cell suspension containing 7-8 x 104 cells were plated in test 
tubes. Substances dissolved in 2ul of DMSO were added. The medium of 
control wells contained an equal volume of DMSO. After two days of in-
cubation, cells were labeled for 2 h with 0.3 uCi 3H-thymidine (NEN) per 
well. 1 ml was used for determination of cell number (Coulter counter 
ZM). From the remaining part cells were harvested by centrifugation, 
washed with PBS and sonicated (Branson). After addition of 4 ml of 10 % 
trichloroacetic acid, the acid-insoluble fraction was collected on a 0.4 urn 
filter (Sartorius) and counted after addition of 10 ml scintillation liquid 
(Quickszint 212, Zinnser) in a LS 1801 scintillation counter (Beckman). 
* HEPES: 4-(2-Hydroxyethyl)-l-piperazineethanesulfonic acid 
MDA-MB 231 Human Breast Cancer Cells13) 
Cells were grown in McCoy 5a medium (Boehringer, Mannheim) supple-
mented with 10 % newborn calf serum (NCS) (Gibco) and gentamycine 
(40 |ig/ml). Cells were grown in a humidified incubator in 5 % C 0 2 at 37°. 
Cells were harvested with 0.05 % trypsine-0.02 % EDTA in 0.15 M NaCl 
and approximately 2 x 104 cells in 2 ml were plated in six-well dishes (Lin-
bro). Two days later cells were switched to a medium containing 5 % NCS 
and the substances, dissolved in 2 ul DMSO. The medium of control wells 
contained an equal volume of DMSO. Two days later, cells were labeled 
for 2 h with 0.3 uCi 3H-thymidine per well. 1 ml was used for determina-
tion of cell number. The remaining cells were harvested by centrifugation, 
washed with PBS and sonicated. After addition of 4 ml of 10 % trichloro-
acetic acid, the acid insoluble fraction was collected on a 0.4 um filter and 
counted after addition of 10 ml scintillation liquid in a scintillation coun-
ter. 
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